A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.
Regulatory authorities have indicated that new drugs to treat type 2 diabetes (T2D) should not be associated with an unacceptable increase in cardiovascular risk. Human genetics may be able to guide development of antidiabetic therapies by predicting cardiovascular and other health endpoints. We the...
| Главные авторы: | , , , , , |
|---|---|
| Формат: | Journal article |
| Язык: | English |
| Опубликовано: |
American Association for the Advancement of Science
2016
|